A slow disengagement from platinum-based chemotherapy for patients with advanced non-small cell lung cancer.
Ballas
Marc S
MS
Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20889, USA.
Dennis
Phillip A
PA
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D003967:Diarrhea / Q000139:chemically induced; D004334:Drug Administration Schedule; D006801:Humans; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D020714:Maximum Tolerated Dose; D009503:Neutropenia / Q000139:chemically induced; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D010984:Platinum / Q000627:therapeutic use*; D015996:Survival Rate; D013997:Time Factors
D010984:Platinum; D000077146:Irinotecan; D017239:Paclitaxel; D002166:Camptothecin